Beta-Lactams for Treatment of Cns Disorders

摘要

The present invention relates to novel compounds of formula (I): wherein - represents a single or a double bond; R is a radical selected from: in which R₁ is halogen, cyano, C_1-4 alkyl, C_1-4 alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3; R₂ is hydrogen or C_1-4 alkyl; R₃ is hydrogen, hydroxy or C_1-4 alkyl; R₄ is hydrogen or R₄ together with R₃ represents -O or -CH2; R₅ is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_1-4 alkyl, hydroxy, cyano, C_1-4 alkoxy, trifluoromethoxy, halogen or S(O)qC_1-4 alkyl; R₆ and R₇ independently are hydrogen, cyano, C_1-4 alkyl; R₈ is (CH₂)rR₁₀; R₉ is hydrogen, halogen, C_3-7 cycloalkyl, hydroxy, nitro, cyano or C_1-4 alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_1-4 alkoxy; R₁₀ is hydrogen or C_3-7 cycloalkyl; n is 1 or 2; q is 0, 1 or 2; r is 0 or an integer from 1 to 4; or a pharmaceutically acceptable salt or a solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of the serotonin reuptake transporter protein